subscribe
 

High payload targeted drug delivery

20th June 2014


CEA-Leti and Akrivis Technologies are collaborating to develop an adaptable, efficient and highly-targeted drug delivery platform for chemotherapy and other treatments that require a high concentration of powerful drugs to be delivered precisely to targeted cells.

The new platform will be based on Akrivis Technologies’ Z–TECT technology that targets and detects unusually low levels of proteins and molecular targets and Leti’s Lipidot nanovector delivery capability.

Z–TECT and Lipidot technologies

Z–TECT is a technology platform that combines nanotechnology, molecular detection and immunology to provide high sensitivity and detection levels across multiple immunoassays and other assay formats, from colorimetric to fluorescent detection in vitro and imaging in vivo.

The Lipidot technology is a nano-delivery platform based on very small droplets of oil that encapsulate and carry drugs, fluorescent imaging agents or any other lipophilic payload to targeted cells for diagnosis or treatment.

By combining their delivery and targeting platforms, Leti and Akrivis intend to develop a new, more efficient and safer platform to deliver high payloads specifically to targeted cells.

The resulting targeted nanoparticles will be optimised in a first phase for research and pre-clinical in vitro and in vivo applications. Then, in a second phase, they will be further developed clinically for in vitro diagnostics, in vivo imaging and targeted therapy.

“The new targeted nanoparticles jointly developed by Leti and Akrivis Technologies will dramatically improve the effectiveness of both diagnosis and treatment of diseases and reduce dangerous or unpleasant side effects,” said Patrick Boisseau, head of Leti’s nanomedicine program and chairman of the European Technology Platform – Nanomedicine (ETPN). “While specifically designed to meet the needs of pharmaceutical and biotech companies, the new platform will be customisable for other end-user applications such as diagnostics and theranostics.”

“Detecting disease earlier and delivering the precise drug dosage at the right place at the right moment are major steps towards improving patient diagnosis and treatment as well as controlling healthcare costs,” said Joel Berniac, CEO of Akrivis Technologies. “Akrivis and Leti have highly complementary nanomed technology platforms that will come together and offer physicians powerful new options for diagnosis and treatment.”





Subscribe

Subscribe



Newsbrief

FREE NEWSBRIEF SUBSCRIPTION

To receive the Scientist Live weekly email NewsBrief please enter your details below

Twitter Icon © Setform Limited
subscribe